Close
Smartlab Europe
Inizio Ignite

Clinical Trials

AbbVie’s Investigational HCV Regimen Receives U.S. FDA Breakthrough Therapy Designation

AbbVie a global biopharmaceutical company announced that the U.S. FDA has granted Breakthrough Therapy Designation (BTD) for the investigational, pan-genotypic regimen of glecaprevir (ABT-493)/pibrentasvir (ABT-530) (G/P) for the treatment of patients with chronic hepatitis C virus (HCV) who failed...

Genocea’s Immunotherapy GEN-003 Demonstrates Significant Reduction of Viral Shedding in Phase 2b Clinical Trial

Genocea Biosciences, a biopharmaceutical company developing T cell-directed vaccines and immunotherapies announced positive results from its ongoing Phase 2b trial evaluating a new Phase 3-ready formulation of GEN-003 for the treatment of genital herpes. The study...

Threshold Announces Interim Results from Tarloxotinib Program and its Plans to Focus on Evofosfamide and Earlier-Stage Opportunities

Threshold Pharmaceuticals, Inc, a clinical-stage biopharmaceutical company specializing in the development of novel pharmaceutical products and technologies for the treatment of cancer, announced interim data from its two Phase 2 proof-of-concept clinical trials of tarloxotinib Outlined...

Novartis announces AMG 334 significantly reduces monthly migraine days in people with episodic migraine

Novartis announced positive topline results from ARISE, the first Phase III study evaluating the efficacy and safety of monthly subcutaneous AMG 334 (erenumab) 70mg in episodic migraine prevention. The study met the primary endpoint, demonstrating a...

Advaxis Inc starts New Manufacturing/Laboratory Facility in Princeton

Advaxis, Inc a clinical stage biotechnology company developing cancer immunotherapies, will unveil its new state-of-the-art manufacturing facility in Princeton, N.J., with remarks from Governor Chris Christie, BioNJ President and CEO Debbie Hart and Advaxis CEO Daniel O’Connor. ...

Astrazeneca says asthma drug shows positive results in phase III trials

Results from pivotal Phase III trials presented at the ERS International Congress demonstrated that adding benralizumab to standard-of-care medicine significantly reduced exacerbations and improved lung function and asthma symptoms in severe asthma patients with an eosinophilic phenotype, as indicated...

CiToxLAB appoints Alan Bartlett as Senior Director, Global Laboratory Operations

CiToxLAB, a leading CRO in the field of non-clinical research, announces that Alan Bartlett has joined the company as Senior Director, Global Laboratory Operations, bringing with him 30 years’ experience in the development and implementation of laboratory support in...

Subscribe

- Never miss a story with notifications

- Gain full access to our premium content

- Browse free from any location or device.

Must read

Translate »